Hubbry Logo
Notch signaling pathwayNotch signaling pathwayMain
Open search
Notch signaling pathway
Community hub
Notch signaling pathway
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Notch signaling pathway
Notch signaling pathway
from Wikipedia
Notch-mediated juxtacrine signal between adjacent cells
Notch signaling steps

The Notch signaling pathway is a highly conserved cell signaling system present in most animals.[1] Mammals possess four different notch receptors, referred to as NOTCH1, NOTCH2, NOTCH3, and NOTCH4.[2] The notch receptor is a single-pass transmembrane receptor protein. It is a hetero-oligomer composed of a large extracellular portion, which associates in a calcium-dependent, non-covalent interaction with a smaller piece of the notch protein composed of a short extracellular region, a single transmembrane-pass, and a small intracellular region.[3]

Notch signaling promotes proliferative signaling during neurogenesis, and its activity is inhibited by Numb to promote neural differentiation. It plays a major role in the regulation of embryonic development.

Notch signaling is dysregulated in many cancers, and faulty notch signaling is implicated in many diseases, including T-cell acute lymphoblastic leukemia (T-ALL),[4] cerebral autosomal-dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), multiple sclerosis, Tetralogy of Fallot, and Alagille syndrome. Inhibition of notch signaling inhibits the proliferation of T-cell acute lymphoblastic leukemia in both cultured cells and a mouse model.[5][6]

Discovery

[edit]

In 1914, John S. Dexter noticed the appearance of a notch in the wings of the fruit fly Drosophila melanogaster. The alleles of the gene were identified in 1917 by American evolutionary biologist Thomas Hunt Morgan.[7][8] Its molecular analysis and sequencing was independently undertaken in the 1980s by Spyros Artavanis-Tsakonas and Michael W. Young.[9][10] Alleles of the two C. elegans Notch genes were identified based on developmental phenotypes: lin-12[11] and glp-1.[12][13] The cloning and partial sequence of lin-12 was reported at the same time as Drosophila Notch by Iva Greenwald.[14]

Mechanism

[edit]

The Notch protein spans the cell membrane, with part of it inside and part outside. Ligand proteins binding to the extracellular domain induce proteolytic cleavage and release of the intracellular domain, which enters the cell nucleus to modify gene expression.[15]

The cleavage model was first proposed in 1993 based on work done with Drosophila Notch and C. elegans lin-12,[16][17] informed by the first oncogenic mutation affecting a human Notch gene.[18] Compelling evidence for this model was provided in 1998 by in vivo analysis in Drosophila by Gary Struhl[19] and in cell culture by Raphael Kopan.[20] Although this model was initially disputed,[1] the evidence in favor of the model was irrefutable by 2001.[21][22]

The receptor is normally triggered via direct cell-to-cell contact, in which the transmembrane proteins of the cells in direct contact form the ligands that bind the notch receptor. The Notch binding allows groups of cells to organize themselves such that, if one cell expresses a given trait, this may be switched off in neighbouring cells by the intercellular notch signal. In this way, groups of cells influence one another to make large structures. Thus, lateral inhibition mechanisms are key to Notch signaling. lin-12 and Notch mediate binary cell fate decisions, and lateral inhibition involves feedback mechanisms to amplify initial differences.[21]

The Notch cascade consists of Notch and Notch ligands, as well as intracellular proteins transmitting the notch signal to the cell's nucleus. The Notch/Lin-12/Glp-1 receptor family[23] was found to be involved in the specification of cell fates during development in Drosophila and C. elegans.[24]

The intracellular domain of Notch forms a complex with CBF1 and Mastermind to activate transcription of target genes. The structure of the complex has been determined.[25][26]

Pathway

[edit]

Maturation of the notch receptor involves cleavage at the prospective extracellular side during intracellular trafficking in the Golgi complex.[27] This results in a bipartite protein, composed of a large extracellular domain linked to the smaller transmembrane and intracellular domain. Binding of ligand promotes two proteolytic processing events; as a result of proteolysis, the intracellular domain is liberated and can enter the nucleus to engage other DNA-binding proteins and regulate gene expression.

Notch and most of its ligands are transmembrane proteins, so the cells expressing the ligands typically must be adjacent to the notch expressing cell for signaling to occur.[citation needed] The notch ligands are also single-pass transmembrane proteins and are members of the DSL (Delta/Serrate/LAG-2) family of proteins. In Drosophila melanogaster (the fruit fly), there are two ligands named Delta and Serrate. In mammals, the corresponding names are Delta-like and Jagged. In mammals there are multiple Delta-like and Jagged ligands, as well as possibly a variety of other ligands, such as F3/contactin.[28]

In the nematode C. elegans, two genes encode homologous proteins, glp-1 and lin-12. There has been at least one report that suggests that some cells can send out processes that allow signaling to occur between cells that are as much as four or five cell diameters apart.[citation needed]

The notch extracellular domain is composed primarily of small cystine-rich motifs called EGF-like repeats.[29]

Notch 1, for example, has 36 of these repeats. Each EGF-like repeat is composed of approximately 40 amino acids, and its structure is defined largely by six conserved cysteine residues that form three conserved disulfide bonds. Each EGF-like repeat can be modified by O-linked glycans at specific sites.[30] An O-glucose sugar may be added between the first and second conserved cysteines, and an O-fucose may be added between the second and third conserved cysteines. These sugars are added by an as-yet-unidentified O-glucosyltransferase (except for Rumi), and GDP-fucose Protein O-fucosyltransferase 1 (POFUT1), respectively. The addition of O-fucose by POFUT1 is absolutely necessary for notch function, and, without the enzyme to add O-fucose, all notch proteins fail to function properly. As yet, the manner by which the glycosylation of notch affects function is not completely understood.

The O-glucose on notch can be further elongated to a trisaccharide with the addition of two xylose sugars by xylosyltransferases, and the O-fucose can be elongated to a tetrasaccharide by the ordered addition of an N-acetylglucosamine (GlcNAc) sugar by an N-Acetylglucosaminyltransferase called Fringe, the addition of a galactose by a galactosyltransferase, and the addition of a sialic acid by a sialyltransferase.[31]

To add another level of complexity, in mammals there are three Fringe GlcNAc-transferases, named lunatic fringe, manic fringe, and radical fringe. These enzymes are responsible for something called a "fringe effect" on notch signaling.[32] If Fringe adds a GlcNAc to the O-fucose sugar then the subsequent addition of a galactose and sialic acid will occur. In the presence of this tetrasaccharide, notch signals strongly when it interacts with the Delta ligand, but has markedly inhibited signaling when interacting with the Jagged ligand.[33] The means by which this addition of sugar inhibits signaling through one ligand, and potentiates signaling through another is not clearly understood.

Once the notch extracellular domain interacts with a ligand, an ADAM-family metalloprotease called ADAM10, cleaves the notch protein just outside the membrane.[34] This releases the extracellular portion of notch (NECD), which continues to interact with the ligand. The ligand plus the notch extracellular domain is then endocytosed by the ligand-expressing cell. There may be signaling effects in the ligand-expressing cell after endocytosis; this part of notch signaling is a topic of active research.[citation needed] After this first cleavage, an enzyme called γ-secretase (which is implicated in Alzheimer's disease) cleaves the remaining part of the notch protein just inside the inner leaflet of the cell membrane of the notch-expressing cell. This releases the intracellular domain of the notch protein (NICD), which then moves to the nucleus, where it can regulate gene expression by activating the transcription factor CSL. It was originally thought that these CSL proteins suppressed Notch target transcription. However, further research showed that, when the intracellular domain binds to the complex, it switches from a repressor to an activator of transcription.[35] Other proteins also participate in the intracellular portion of the notch signaling cascade.[36]

Ligand interactions

[edit]
Crystal structure of the Notch1-DLL4 complex depicted as the interaction is predicted to occur between two cells (PDB ID: 4XLW)

Notch signaling is initiated when Notch receptors on the cell surface engage ligands presented in trans on opposing cells. Despite the expansive size of the Notch extracellular domain, it has been demonstrated that EGF domains 11 and 12 are the critical determinants for interactions with Delta.[37] Additional studies have implicated regions outside of Notch EGF11-12 in ligand binding. For example, Notch EGF domain 8 plays a role in selective recognition of Serrate/Jagged[38] and EGF domains 6-15 are required for maximal signaling upon ligand stimulation.[39] A crystal structure of the interacting regions of Notch1 and Delta-like 4 (Dll4) provided a molecular-level visualization of Notch-ligand interactions, and revealed that the N-terminal MNNL (or C2) and DSL domains of ligands bind to Notch EGF domains 12 and 11, respectively.[40] The Notch1-Dll4 structure also illuminated a direct role for Notch O-linked fucose and glucose moieties in ligand recognition, and rationalized a structural mechanism for the glycan-mediated tuning of Notch signaling.[40]

Synthetic Notch signaling

[edit]

It is possible to engineer synthetic Notch receptors by replacing the extracellular receptor and intracellular transcriptional domains with other domains of choice. This allows researchers to select which ligands are detected, and which genes are upregulated in response. Using this technology, cells can report or change their behavior in response to contact with user-specified signals, facilitating new avenues of both basic and applied research into cell-cell signaling.[41] Notably, this system allows multiple synthetic pathways to be engineered into a cell in parallel.[42][43]

Function

[edit]

The Notch signaling pathway is important for cell-cell communication, which involves gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life. Notch signaling also has a role in the following processes:

It has also been found that Rex1 has inhibitory effects on the expression of notch in mesenchymal stem cells, preventing differentiation.[58]

Role in embryogenesis

[edit]

The Notch signaling pathway plays an important role in cell-cell communication, and further regulates embryonic development.

Embryo polarity

[edit]

Notch signaling is required in the regulation of polarity. For example, mutation experiments have shown that loss of Notch signaling causes abnormal anterior-posterior polarity in somites.[59] Also, Notch signaling is required during left-right asymmetry determination in vertebrates.[60]

Early studies in the nematode model organism C. elegans indicate that Notch signaling has a major role in the induction of mesoderm and cell fate determination.[12] As mentioned previously, C. elegans has two genes that encode for partially functionally redundant Notch homologs, glp-1 and lin-12.[61] During C. elegans, GLP-1, the C. elegans Notch homolog, interacts with APX-1, the C. elegans Delta homolog. This signaling between particular blastomeres induces differentiation of cell fates and establishes the dorsal-ventral axis.[62]

Role in somitogenesis

[edit]

Notch signaling is central to somitogenesis. In 1995, Notch1 was shown to be important for coordinating the segmentation of somites in mice.[63] Further studies identified the role of Notch signaling in the segmentation clock. These studies hypothesized that the primary function of Notch signaling does not act on an individual cell, but coordinates cell clocks and keep them synchronized. This hypothesis explained the role of Notch signaling in the development of segmentation and has been supported by experiments in mice and zebrafish.[64][65][66] Experiments with Delta1 mutant mice that show abnormal somitogenesis with loss of anterior/posterior polarity suggest that Notch signaling is also necessary for the maintenance of somite borders.[63]

During somitogenesis, a molecular oscillator in paraxial mesoderm cells dictates the precise rate of somite formation. A clock and wavefront model has been proposed in order to spatially determine the location and boundaries between somites. This process is highly regulated as somites must have the correct size and spacing in order to avoid malformations within the axial skeleton that may potentially lead to spondylocostal dysostosis. Several key components of the Notch signaling pathway help coordinate key steps in this process. In mice, mutations in Notch1, Dll1 or Dll3, Lfng, or Hes7 result in abnormal somite formation. Similarly, in humans, the following mutations have been seen to lead to development of spondylocostal dysostosis: DLL3, LFNG, or HES7.[67]

Role in epidermal differentiation

[edit]

Notch signaling is known to occur inside ciliated, differentiating cells found in the first epidermal layers during early skin development.[68] Furthermore, it has found that presenilin-2 works in conjunction with ARF4 to regulate Notch signaling during this development.[69] However, it remains to be determined whether gamma-secretase has a direct or indirect role in modulating Notch signaling.

Role in central nervous system development and function

[edit]
Notch-Delta lateral inhibition in neural stem cells, resulting in the generation of neuronal and glial progenitors.

Early findings on Notch signaling in central nervous system (CNS) development were performed mainly in Drosophila with mutagenesis experiments. For example, the finding that an embryonic lethal phenotype in Drosophila was associated with Notch dysfunction[70] indicated that Notch mutations can lead to the failure of neural and Epidermal cell segregation in early Drosophila embryos. In the past decade, advances in mutation and knockout techniques allowed research on the Notch signaling pathway in mammalian models, especially rodents.

The Notch signaling pathway was found to be critical mainly for neural progenitor cell (NPC) maintenance and self-renewal. In recent years, other functions of the Notch pathway have also been found, including glial cell specification,[71][72] neurites development,[73] as well as learning and memory.[74]

Neuron cell differentiation

[edit]

The Notch pathway is essential for maintaining NPCs in the developing brain. Activation of the pathway is sufficient to maintain NPCs in a proliferating state, whereas loss-of-function mutations in the critical components of the pathway cause precocious neuronal differentiation and NPC depletion.[45] Modulators of the Notch signal, e.g., the Numb protein are able to antagonize Notch effects, resulting in the halting of cell cycle and the differentiation of NPCs.[75][76] Conversely, the fibroblast growth factor pathway promotes Notch signaling to keep stem cells of the cerebral cortex in the proliferative state, amounting to a mechanism regulating cortical surface area growth and, potentially, gyrification.[77][78] In this way, Notch signaling controls NPC self-renewal as well as cell fate specification.

A non-canonical branch of the Notch signaling pathway that involves the phosphorylation of STAT3 on the serine residue at amino acid position 727 and subsequent Hes3 expression increase (STAT3-Ser/Hes3 Signaling Axis) has been shown to regulate the number of NPCs in culture and in the adult rodent brain.[79]

In adult rodents and in cell culture, Notch3 promotes neuronal differentiation, having a role opposite to Notch1/2.[80] This indicates that individual Notch receptors can have divergent functions, depending on cellular context.

Neurite development

[edit]

In vitro studies show that Notch can influence neurite development.[73] In vivo, deletion of the Notch signaling modulator, Numb, disrupts neuronal maturation in the developing cerebellum,[81] whereas deletion of Numb disrupts axonal arborization in sensory ganglia.[82] Although the mechanism underlying this phenomenon is not clear, together these findings suggest Notch signaling might be crucial in neuronal maturation.

Gliogenesis

[edit]

In gliogenesis, Notch appears to have an instructive role that can directly promote the differentiation of many glial cell subtypes.[71][72] For example, activation of Notch signaling in the retina favors the generation of Muller glia cells at the expense of neurons, whereas reduced Notch signaling induces production of ganglion cells, causing a reduction in the number of Muller glia.[45]

Adult brain function

[edit]

Apart from its role in development, evidence shows that Notch signaling is also involved in neuronal apoptosis, neurite retraction, and neurodegeneration of ischemic stroke in the brain[83] In addition to developmental functions, Notch proteins and ligands are expressed in cells of the adult nervous system,[84] suggesting a role in CNS plasticity throughout life. Adult mice heterozygous for mutations in either Notch1 or Cbf1 have deficits in spatial learning and memory.[74] Similar results are seen in experiments with presenilins1 and 2, which mediate the Notch intramembranous cleavage. To be specific, conditional deletion of presenilins at 3 weeks after birth in excitatory neurons causes learning and memory deficits, neuronal dysfunction, and gradual neurodegeneration.[85] Several gamma secretase inhibitors that underwent human clinical trials in Alzheimer's disease and MCI patients resulted in statistically significant worsening of cognition relative to controls, which is thought to be due to its incidental effect on Notch signalling.[86]

Role in cardiovascular development

[edit]

The Notch signaling pathway is a critical component of cardiovascular formation and morphogenesis in both development and disease. It is required for the selection of endothelial tip and stalk cells during sprouting angiogenesis.[87]

Cardiac development

[edit]

Notch signal pathway plays a crucial role in at least three cardiac development processes: Atrioventricular canal development, myocardial development, and cardiac outflow tract (OFT) development.[88]

Atrioventricular (AV) canal development

[edit]
AV boundary formation
Notch signaling can regulate the atrioventricular boundary formation between the AV canal and the chamber myocardium.
Studies have revealed that both loss- and gain-of-function of the Notch pathway results in defects in AV canal development.[88] In addition, the Notch target genes HEY1 and HEY2 are involved in restricting the expression of two critical developmental regulator proteins, BMP2 and Tbx2, to the AV canal.[89][90]
AV epithelial-mesenchymal transition (EMT)
Notch signaling is also important for the process of AV EMT, which is required for AV canal maturation. After the AV canal boundary formation, a subset of endocardial cells lining the AV canal are activated by signals emanating from the myocardium and by interendocardial signaling pathways to undergo EMT.[88] Notch1 deficiency results in defective induction of EMT. Very few migrating cells are seen and these lack mesenchymal morphology.[91] Notch may regulate this process by activating matrix metalloproteinase2 (MMP2) expression, or by inhibiting vascular endothelial (VE)-cadherin expression in the AV canal endocardium[92] while suppressing the VEGF pathway via VEGFR2.[93] In RBPJk/CBF1-targeted mutants, the heart valve development is severely disrupted, presumably because of defective endocardial maturation and signaling.[91]

Ventricular development

[edit]

Some studies in Xenopus[94] and in mouse embryonic stem cells[95] indicate that cardiomyogenic commitment and differentiation require Notch signaling inhibition. Active Notch signaling is required in the ventricular endocardium for proper trabeculae development subsequent to myocardial specification by regulating BMP10, NRG1, and EphrinB2 expression.[49] Notch signaling sustains immature cardiomyocyte proliferation in mammals [96][97][98] and zebrafish.[99] A regulatory correspondence likely exists between Notch signaling and Wnt signaling, whereby upregulated Wnt expression downregulates Notch signaling, and a subsequent inhibition of ventricular cardiomyocyte proliferation results. This proliferative arrest can be rescued using Wnt inhibitors.[100]

The downstream effector of Notch signaling, HEY2, was also demonstrated to be important in regulating ventricular development by its expression in the interventricular septum and the endocardial cells of the cardiac cushions.[101] Cardiomyocyte and smooth muscle cell-specific deletion of HEY2 results in impaired cardiac contractility, malformed right ventricle, and ventricular septal defects.[102]

Ventricular outflow tract development

[edit]

During development of the aortic arch and the aortic arch arteries, the Notch receptors, ligands, and target genes display a unique expression pattern.[103] When the Notch pathway was blocked, the induction of vascular smooth muscle cell marker expression failed to occur, suggesting that Notch is involved in the differentiation of cardiac neural crest cells into vascular cells during outflow tract development.

Angiogenesis

[edit]

Endothelial cells use the Notch signaling pathway to coordinate cellular behaviors during the blood vessel sprouting that occurs sprouting angiogenesis.[104][105][106][107]

Activation of Notch takes place primarily in "connector" cells and cells that line patent stable blood vessels through direct interaction with the Notch ligand, Delta-like ligand 4 (Dll4), which is expressed in the endothelial tip cells.[108] VEGF signaling, which is an important factor for migration and proliferation of endothelial cells,[109] can be downregulated in cells with activated Notch signaling by lowering the levels of Vegf receptor transcript.[110] Zebrafish embryos lacking Notch signaling exhibit ectopic and persistent expression of the zebrafish ortholog of VEGF3, flt4, within all endothelial cells, while Notch activation completely represses its expression.[111]

Notch signaling may be used to control the sprouting pattern of blood vessels during angiogenesis. When cells within a patent vessel are exposed to VEGF signaling, only a restricted number of them initiate the angiogenic process. Vegf is able to induce DLL4 expression. In turn, DLL4 expressing cells down-regulate Vegf receptors in neighboring cells through activation of Notch, thereby preventing their migration into the developing sprout. Likewise, during the sprouting process itself, the migratory behavior of connector cells must be limited to retain a patent connection to the original blood vessel.[108]

Role in endocrine development

[edit]

During development, definitive endoderm and ectoderm differentiates into several gastrointestinal epithelial lineages, including endocrine cells. Many studies have indicated that Notch signaling has a major role in endocrine development.

Pancreatic development

[edit]

The formation of the pancreas from endoderm begins in early development. The expression of elements of the Notch signaling pathway have been found in the developing pancreas, suggesting that Notch signaling is important in pancreatic development.[112][113] Evidence suggests Notch signaling regulates the progressive recruitment of endocrine cell types from a common precursor,[114] acting through two possible mechanisms. One is the "lateral inhibition", which specifies some cells for a primary fate but others for a secondary fate among cells that have the potential to adopt the same fate. Lateral inhibition is required for many types of cell fate determination. Here, it could explain the dispersed distribution of endocrine cells within pancreatic epithelium.[115] A second mechanism is "suppressive maintenance", which explains the role of Notch signaling in pancreas differentiation. Fibroblast growth factor10 is thought to be important in this activity, but the details are unclear.[116][117]

Intestinal development

[edit]

The role of Notch signaling in the regulation of gut development has been indicated in several reports. Mutations in elements of the Notch signaling pathway affect the earliest intestinal cell fate decisions during zebrafish development.[118] Transcriptional analysis and gain of function experiments revealed that Notch signaling targets Hes1 in the intestine and regulates a binary cell fate decision between adsorptive and secretory cell fates.[118]

Bone development

[edit]

Early in vitro studies have found the Notch signaling pathway functions as down-regulator in osteoclastogenesis and osteoblastogenesis.[119] Notch1 is expressed in the mesenchymal condensation area and subsequently in the hypertrophic chondrocytes during chondrogenesis.[120] Overexpression of Notch signaling inhibits bone morphogenetic protein2-induced osteoblast differentiation. Overall, Notch signaling has a major role in the commitment of mesenchymal cells to the osteoblastic lineage and provides a possible therapeutic approach to bone regeneration.[53]

Role in cell cycle control

[edit]

Notch signaling is critical for cell fate identity and differentiation and regulates these processes in part by controlling cell cycle progression. Specifically, Notch has been shown to promote cell cycle progression at the G1/S transition in various systems.

Photoreceptor development

[edit]

In Drosophila eye development, photoreceptors undergo two waves of differentiation, where five out of eight photoreceptors differentiate in the first wave (R8, R2, R5, R3, and R4), and the other three differentiate in the second wave (R1, R6, and R7).[121] Notch has been shown to promote the second mitotic wave in Drosophila eye development.[122] Specifically, it mediates the G1/S transition by promoting dE2F activation (Drosophila E2F), a member of the E2F transcription factor family, which regulates the expression of genes important for cell proliferation, specifically those involved in the G1/S transition.[122][123] Notch does this by inhibiting RBF1 (the Drosophila homolog of the tumor suppressor Rb), which represses dE2F.[122] Additionally, Notch is required for cyclin A activation, which accumulates during the G1/S transition and may be involved in S phase onset.[122]

Health and disease

[edit]

The role of Notch signaling in cell cycle regulation also has implications in health and disease. For example, Notch has been found to promote the expression of cyclin D3 and Cdk4/6 in human T-cells, thereby promoting the phosphorylation of Rb and facilitating the G1/S transition, implicating its role in cancer as several gain-of-function mutations in NOTCH1 have been identified in human acute T-cell lymphoblastic leukemias and lymphomas.[124][125] Additionally, in ventricular cardiomyocytes, which stop dividing shortly after birth, NOTCH2 signaling activation promotes cell cycle reentry.[98] It induces the expression and nuclear translocation of cyclin D, which along with Cdk4/6 promotes the phosphorylation of Rb and causes cell cycle progression through the G1/S transition.[98] This suggests that Notch signaling might regulate ventricular growth as well as cardiomyocyte regeneration, though this is unclear.[98]

Migratory identity

[edit]

In the zebrafish trunk neural crest (TNC), cells migrate collectively in single-file chains, with a cell "leader" at the front of the chain that instructs the directionality of the trailing "follower" cells.[126] Notch has been found to specify cell migratory identity in the trunk neural crest – specifically, high Notch specifies leaders while low Notch specifies followers.[127] Further, cell cycle progression required for migration is regulated by Notch such that leader cells with high Notch activity quickly undergo the G1/S transition while cells with low Notch activity remain in the G1 phase for longer and thus become followers.[127]

Role in cancer

[edit]

Leukemia

[edit]

Aberrant Notch signaling is a driver of T cell acute lymphoblastic leukemia (T-ALL)[128] and is mutated in at least 65% of all T-ALL cases.[129] Notch signaling can be activated by mutations in Notch itself, inactivating mutations in FBXW7 (a negative regulator of Notch1), or rarely by t(7;9)(q34;q34.3) translocation. In the context of T-ALL, Notch activity cooperates with additional oncogenic lesions such as c-MYC to activate anabolic pathways such as ribosome and protein biosynthesis thereby promoting leukemia cell growth.[130]

Urothelial bladder cancer

[edit]

Loss of Notch activity is a driving event in urothelial cancer. A study identified inactivating mutations in components of the Notch pathway in over 40% of examined human bladder carcinomas. In mouse models, genetic inactivation of Notch signaling results in Erk1/2 phosphorylation leading to tumorigenesis in the urinary tract.[131] As not all NOTCH receptors are equally involved in the urothelial bladder cancer, 90% of samples in one study had some level of NOTCH3 expression, suggesting that NOTCH3 plays an important role in urothelial bladder cancer. A higher level of NOTCH3 expression was observed in high-grade tumors, and a higher level of positivity was associated with a higher mortality risk. NOTCH3 was identified as an independent predictor of poor outcome. Therefore, it is suggested that NOTCH3 could be used as a marker for urothelial bladder cancer-specific mortality risk. It was also shown that NOTCH3 expression could be a prognostic immunohistochemical marker for clinical follow-up of urothelial bladder cancer patients, contributing to a more individualized approach by selecting patients to undergo control cystoscopy after a shorter time interval.[132]

Liver cancer

[edit]

In hepatocellular carcinoma, for instance, it was suggesting that AXIN1 mutations would provoke Notch signaling pathway activation, fostering the cancer development, but a recent study demonstrated that such an effect cannot be detected.[133] Thus the exact role of Notch signaling in the cancer process awaits further elucidation.

Notch inhibitors

[edit]

The involvement of Notch signaling in many cancers has led to investigation of notch inhibitors (especially gamma-secretase inhibitors) as cancer treatments which are in different phases of clinical trials.[2][134] As of 2013 at least 7 notch inhibitors were in clinical trials.[135] MK-0752 has given promising results in an early clinical trial for breast cancer.[136] Preclinical studies showed beneficial effects of gamma-secretase inhibitors in endometriosis,[137] a disease characterised by increased expression of notch pathway constituents.[138][139] Several notch inhibitors, including the gamma-secretase inhibitor LY3056480, are being studied for their potential ability to regenerate hair cells in the cochlea, which could lead to treatments for hearing loss and tinnitus.[140][141]

Mathematical modeling

[edit]

Mathematical modeling in Notch-Delta signaling has become a pivotal tool in understanding pattern formation driven by cell-cell interactions, particularly in the context of lateral-inhibition mechanisms. The Collier model,[142] a cornerstone in this field, employs a system of coupled ordinary differential equations to describe the feedback loop between adjacent cells. The model is defined by the equations:

where and represent the levels of Notch and Delta activity in cell , respectively. Functions and are typically Hill functions, reflecting the regulatory dynamics of the signaling process. The term denotes the average level of Delta activity in the cells adjacent to cell , integrating juxtacrine signaling effects.

Recent extensions of this model incorporate long-range signaling, acknowledging the role of cell protrusions like filopodia (cytonemes) that reach non-neighboring cells.[143][144][145][146] One extended model, often referred to as the -Collier model,[143] introduces a weighting parameter to balance juxtacrine and long-range signaling. The interaction term is modified to include these protrusions, creating a more complex, non-local signaling network. This model is instrumental in exploring pattern formation robustness and biological pattern refinement, considering the stochastic nature of filopodia dynamics and intrinsic noise. The application of mathematical modeling in Notch-Delta signaling has been particularly illuminating in understanding the patterning of sensory organ precursors (SOPs) in the Drosophila's notum and wing margin.[147][148]

The mathematical modeling of Notch-Delta signaling thus provides significant insights into lateral inhibition mechanisms and pattern formation in biological systems. It enhances the understanding of cell-cell interaction variations leading to diverse tissue structures, contributing to developmental biology and offering potential therapeutic pathways in diseases related to Notch-Delta dysregulation.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
The Notch signaling pathway is an evolutionarily conserved, short-range cell-to-cell communication mechanism essential for regulating , proliferation, differentiation, and across metazoan species. First identified over 110 years ago in through genetic studies of the notched wing mutation, it enables precise coordination of developmental processes and maintenance of tissue homeostasis in adults. In mammals, the pathway comprises four single-pass transmembrane receptors (NOTCH1–4) and five canonical ligands from two families: Delta-like (DLL1, DLL3, DLL4) and Jagged (JAG1, JAG2). These receptors feature a large extracellular domain with multiple epidermal growth factor (EGF)-like repeats for ligand binding, a negative regulatory region (NRR) that maintains latency, and an intracellular domain (NICD) containing transactivation motifs such as RAM, ankyrin (ANK) repeats, and PEST sequences for degradation control. Ligands, also transmembrane proteins, include a Delta-Serrate-Lag2 (DSL) domain and EGF-like repeats, with Jagged ligands additionally possessing a cysteine-rich domain that modulates interactions. Canonical activation occurs through juxtacrine signaling, where binding on an adjacent cell induces mechanical force and sequential proteolytic cleavages of the receptor: first, S2 cleavage by ADAM metalloproteases exposes the NRR, followed by S3 intramembrane cleavage by the γ-secretase complex, releasing the NICD fragment. The NICD translocates to the nucleus, where it displaces corepressors from the transcription factor CSL (also known as RBPJ in mammals) and recruits co-activators like Mastermind-like (MAML) proteins to form a ternary complex that drives expression of target genes, including the Hes and Hey families of basic helix-loop-helix transcriptional repressors. This process is tightly regulated by post-translational modifications, such as , which influences -receptor affinity, and of -receptor complexes, which generates the pulling force necessary for activation. Non-canonical branches, independent of CSL, involve crosstalk with pathways like Wnt, , and YAP/TAZ, broadening its regulatory scope. The pathway's importance lies in its pleiotropic roles during embryogenesis—such as somitogenesis, , vasculogenesis, and hematopoiesis—and in adult tissues, where it sustains niches, promotes regeneration (e.g., in liver and intestine), and modulates immune responses. Dysregulation disrupts these functions, contributing to developmental disorders and diseases, though therapeutic targeting, such as γ-secretase inhibitors, exploits its context-dependent nature for potential interventions.

History and Discovery

Initial Identification

The Notch gene was first identified in the early through genetic studies in the fruit fly Drosophila melanogaster. In 1910, researchers in Thomas Hunt Morgan's laboratory at isolated a spontaneous mutant fly exhibiting notches in the wing margins and alterations in bristle patterns, which disrupted normal wing vein formation and sensory organ development. This mutation, named Notch after the characteristic wing , was one of the earliest Drosophila loci linked to developmental abnormalities, highlighting its role in patterning and cell fate decisions during embryogenesis. Subsequent breeding experiments confirmed its dominant inheritance for the wing phenotype, position on the , and that many alleles are recessive lethals, establishing it as a key genetic tool for understanding inheritance mechanisms. Molecular characterization of the Notch gene advanced significantly in the 1980s with the advent of cloning techniques. In 1983, Spyros Artavanis-Tsakonas and colleagues at used chromosomal walking to isolate DNA fragments from the Notch locus on the Drosophila X chromosome. Further nucleotide sequencing in 1985 revealed that Notch encodes a large of approximately 310 kDa, featuring (EGF)-like repeats in the extracellular domain, suggestive of a receptor involved in cell-cell interactions and . This work transformed Notch from a classical into a molecularly defined component of developmental signaling, with mutations shown to cause overproduction of neural precursors at the expense of epidermal cells. The identification of mammalian counterparts soon followed, bridging invertebrate and vertebrate biology. In the late 1980s, researchers cloned the first human homolog, termed TAN-1 (translocation-associated Notch homolog 1), from a T-cell acute lymphoblastic leukemia (T-ALL) cell line harboring a chromosomal translocation at 9q34.3. Reported in 1991 by Lance Ellisen and colleagues at , this Notch1 gene was disrupted in multiple T-ALL cases, implicating aberrant Notch signaling in leukemogenesis through potential gain-of-function effects on T-cell proliferation. The protein shared striking structural homology with Notch, including EGF-like repeats and a , underscoring its receptor-like nature. Early comparative studies rapidly established the evolutionary conservation of Notch across metazoans. By the mid-1980s, the lin-12 gene, involved in vulval cell fate decisions, was found to encode a protein homologous to Notch, with shared EGF repeats and roles in binary cell fate choices. Sequence analyses from the 1983 Drosophila cloning and subsequent homolog identifications revealed that core Notch components—receptors, ligands, and effectors—are preserved from nematodes to mammals, reflecting an ancient signaling system essential for multicellular development. This conservation was further evidenced in vertebrates, where multiple Notch paralogs (Notch1-4) emerged via genome duplications, adapting the pathway to complex tissue patterning.

Key Experimental Milestones

In the 1990s, experiments in provided critical evidence for the role of the LIN-12/Notch homolog in facilitating cell-cell communication during vulval induction. These studies demonstrated that ablating the anchor cell or vulval precursor cells (VPCs) led to fate transformations in neighboring cells, such as multiple VPCs adopting the primary fate in the absence of lateral signaling, thereby confirming LIN-12's function in . During the same decade, genetic screens in identified Delta and Serrate as key s for the Notch receptor. Delta was established as a transmembrane essential for ventral-to-dorsal signaling in the wing imaginal disc, where its expression in ventral cells activated Notch in dorsal neighbors to specify boundary fates. Complementarily, Serrate was recognized as a dorsal interacting with Notch via specific EGF-like repeats, promoting dorsoventral compartment signaling and highlighting the pathway's reliance on direct cell-cell contact. In the 2000s, structural biology advanced the mechanistic understanding of Notch activation, with the determination of the crystal structure of the Notch intracellular domain in complex with CSL and Mastermind revealing the architecture of the transcriptional activation complex bound to DNA. This 3.1 Å resolution structure illustrated how the Notch intracellular domain displaces corepressors from CSL to recruit coactivators, solidifying the pathway's direct link to gene regulation. Although high-resolution structures of the full Notch-ligand extracellular complex emerged later, these findings reinforced the juxtacrine nature of signaling inferred from earlier genetics. The foundational contributions to elucidating the Notch pathway were recognized in 2025 with the granted to Spyros Artavanis-Tsakonas, Iva Greenwald, and Gary Struhl for establishing its core mechanisms in through genetic and biochemical studies in . Similarly, the Wiley Prize in Biomedical Sciences was awarded to Artavanis-Tsakonas and Greenwald that year for discovering the genes and biochemical processes underlying Notch signaling.

Molecular Components

Receptors and Ligands

In mammals, the Notch signaling pathway is mediated by four paralogous receptors, Notch1 through Notch4, which function as single-pass transmembrane proteins essential for cell-cell communication. These receptors share a conserved modular architecture, featuring a large extracellular domain (ECD) composed of tandem (EGF)-like repeats—36 in Notch1 and Notch2, 34 in Notch3, and 29 in Notch4—that mediate interactions and contribute to receptor folding and stability through calcium binding. Immediately following the EGF repeats is the negative regulatory region (NRR), which comprises three Lin12-Notch repeats (LNR-A, LNR-B, and LNR-C) and a heterodimerization domain (HD); the LNR modules form a rigid structure that maintains the receptor in an autoinhibited state until engagement.00382-1) The short intracellular domain (ICD) includes the RAM domain for recruiting transcription factors, seven (ANK) repeats that form a scaffold for protein interactions, a (TAD), and a PEST motif regulating ICD stability via proteasomal degradation. The ligands that activate Notch receptors belong to two families: the Delta-like ligands (DLL1, DLL3, and DLL4) and the Jagged ligands (JAG1 and JAG2), all of which are also single-pass transmembrane proteins expressed on the surface of signal-sending cells.30294-0) Each ligand contains an N-terminal DSL (Delta-Serrate-Lag2) domain, a conserved motif critical for high-affinity binding to the EGF repeats of Notch receptors, particularly EGF11-12; this interaction is further stabilized by adjacent EGF-like repeats in the ligand's extracellular region. Jagged ligands additionally possess a unique C-terminal cysteine-rich domain that enhances their membrane tethering and signaling potency compared to Delta-like ligands, while DLL3 exhibits atypical behavior due to its primarily intracellular localization and modified DSL domain, limiting its role as a conventional activator. Ligand-receptor binding typically occurs between adjacent cells, inducing a conformational change in the Notch NRR to expose cleavage sites, though the downstream proteolytic events are detailed elsewhere. The Notch pathway's core components display remarkable evolutionary conservation, originating early in metazoan evolution to regulate binary cell fate decisions. In invertebrates such as Drosophila melanogaster, a single Notch receptor pairs with two ligands, Delta and Serrate (homologous to vertebrate DLL and JAG families, respectively), whereas the nematode Caenorhabditis elegans encodes two receptors, LIN-12 and GLP-1, reflecting simpler signaling needs in these organisms. Vertebrate Notch receptors and ligands arose through two rounds of whole-genome duplication in early chordate evolution, followed by additional lineage-specific duplications, resulting in the expanded mammalian repertoire that enables tissue-specific diversification of signaling outputs. This multiplicity allows for nuanced regulation, as seen in the distinct expression profiles of mammalian paralogs. Notch receptors exhibit dynamic, tissue-specific expression patterns that correlate with their developmental roles. For example, Notch1 is broadly expressed during embryogenesis but becomes enriched in hematopoietic stem and cells, where it directs T-cell lineage commitment in the . Notch2 predominates in marginal zone B cells and splenic development, while Notch3 is prominent in vascular cells, and Notch4 in endothelial cells, underscoring the pathway's adaptability across tissues. Ligand expression is similarly compartmentalized; DLL4 is critical in endothelial tip cells during , and JAG1 in hepatic and pancreatic s, ensuring context-dependent .

Intracellular Effectors

Upon ligand-induced activation, the Notch receptor undergoes sequential proteolytic cleavages by ADAM metalloproteases (S2 cleavage) and the γ-secretase complex (S3 cleavage), releasing the Notch intracellular domain (NICD) from the membrane-tethered form. This approximately 100-kDa fragment, consisting of the RAM domain, ankyrin repeats, transactivation domain (TAD), and PEST sequences for degradation, translocates to the nucleus facilitated by nuclear localization signals (NLS) and importins such as importin α3, α4, and α7. Once in the nucleus, NICD serves as the primary signaling effector, directly modulating transcription without requiring additional cytoplasmic intermediaries. The core nuclear effector of Notch signaling is the CSL transcription factor family (CBF1/RBPJ in mammals, Suppressor of Hairless in , LAG-1 in C. elegans), a that recognizes the RTTGRGAA (Su(H) motif). In the absence of NICD, CSL associates with corepressors like N-CoR, SMRT, and histone deacetylases (e.g., ), repressing target by maintaining in a closed state. NICD binding to the RAM domain of CSL displaces these corepressors, converting CSL into an activator by recruiting co-activators to form a ternary complex. This switch from repression to activation exemplifies the pathway's binary regulatory logic, ensuring precise control over cell fate decisions. Key co-activators in the NICD-CSL complex include Mastermind-like (MAML) proteins, a family of transcriptional adaptors (MAML1-3 in mammals) that bind the NICD repeats and CSL interface via their α-helical domains.00404-X) MAML stabilizes the complex and bridges to histone acetyltransferases such as p300/CBP and GCN5, which acetylate histones (e.g., H3K14, H4K8) to open and facilitate . This enhances transcriptional output, with MAML1 particularly implicated in amplifying Notch signals in developmental contexts like T-cell specification. The primary target genes activated by the NICD-CSL-MAML complex are the Hes (Hairy/Enhancer of Split) and Hey (Hes-related with YRPW motif) families of basic helix-loop-helix (bHLH) transcriptional repressors. These genes, such as Hes1, Hes5, Hey1, and Hey2, contain CSL-binding sites in their promoters and encode proteins that inhibit proneural and differentiation factors (e.g., via binding sequences), thereby maintaining states and promoting during development. For instance, in , Hes1 oscillations driven by Notch sustain neural precursors by repressing Neurogenin. Disruption of these targets underscores their essential role, as Hey1/Hey2 double knockouts lead to severe vascular and cardiac defects.

Signaling Mechanism

Activation and Cleavage Process

The activation of the Notch signaling pathway occurs via juxtacrine signaling, where transmembrane ligands such as Delta-like (DLL1, DLL3, DLL4) or (JAG1, JAG2) on the signal-sending cell engage Notch receptors (NOTCH1-4) on the adjacent signal-receiving cell. This binding induces a conformational change in the receptor's extracellular domain, specifically extending the negative regulatory region (NRR)—three Lin12/Notch repeats (LNR) that wrap around the heterodimerization domain (HD)—that normally autoinhibits cleavage by shielding the S2 site. The exposure of the NRR is essential for initiating proteolytic processing and requires mechanical force often provided by in the ligand-expressing cell. The first proteolytic step involves cleavage at the S2 site within the NRR by ADAM10 metalloprotease (primarily), with contributions from ADAM17 in certain contexts, resulting in the shedding of the majority of the receptor's extracellular domain and generation of a membrane-tethered Notch extracellular truncation (NEXT) fragment. This ectodomain shedding is ligand-dependent and rate-limiting, as it transforms the receptor into a substrate competent for further processing; mutations disrupting S2 cleavage abolish signaling. ADAM10's activity is regulated by its localization and activation state, ensuring precise spatial control during development. Subsequent intramembrane proteolysis occurs at the S3 site within the transmembrane domain of the NEXT fragment, mediated by the γ-secretase complex (comprising or -2, APH-1, PEN-2, and nicastrin), releasing the Notch intracellular domain (NICD) as a soluble fragment that can traffic to the nucleus. The S3 cleavage is constitutive but enhanced by prior S2 processing, and it generates a heterogeneous C-terminal end on NICD due to variable γ-secretase cuts, influencing its stability and activity. This step is inhibited by γ-secretase modulators, highlighting its therapeutic relevance. Endocytosis is critical for amplifying the signal, acting in both sending and receiving cells to facilitate receptor-ligand dissociation and cleavage efficiency. In the signal-sending cell, ligand ubiquitination by E3 ligases (e.g., Neuralized or ) promotes via and , generating pulling force on the bound receptor to disassemble the NRR and expose the S2 site; blocking this with inhibitors like dynasore or shibire mutants in severely impairs Notch activation. In the receiving cell, receptor internalizes the NEXT fragment into endosomes, where localized pools of and γ-secretase enable S3 cleavage, and inhibitors of similarly disrupt signaling output. This bidirectional ensures robust, directional without ligand internalization into the receiving cell.

Transcriptional Regulation

Upon translocation to the nucleus, the Notch intracellular domain (NICD) forms a ternary complex with the DNA-binding protein CSL (also known as RBPJ in mammals) and the co-activator Mastermind-like (MAML), which recruits this complex to specific consensus binding sites in the promoters of target genes. This assembly displaces co-repressor proteins previously bound to CSL, thereby converting CSL from a transcriptional repressor to an activator and initiating gene expression changes essential for cell fate decisions. Structural studies reveal that the ankyrin repeats in NICD interact with the beta-trefoil domain of CSL, while MAML binds to both NICD and CSL, stabilizing the complex and facilitating recruitment of additional co-activators like histone acetyltransferases. The primary transcriptional outputs of this pathway include the upregulation of basic helix-loop-helix (bHLH) transcription factors from the Hes and Hey families, which mediate by repressing proneural genes in neighboring cells. For instance, in neural development, NICD-driven expression of Hes1 and Hey1 suppresses Delta expression, preventing adjacent cells from adopting the same fate and promoting diversification within cell populations. These repressors exhibit oscillatory dynamics due to their short half-lives and autoregulatory feedback, allowing precise temporal control of signaling strength and ensuring robust . While the pathway predominates, non-canonical Notch outputs can occur through phosphorylation-dependent mechanisms independent of CSL, such as NICD-mediated activation of AKT or pathways that influence cell and without direct transcriptional complex formation. These pathways, often triggered by ligand-independent cleavage or post-translational modifications, provide context-specific regulation but are secondary to the primary NICD-CSL-MAML axis. Feedback mechanisms fine-tune Notch activity, including repression via Deltex proteins, which promote NICD ubiquitination and degradation, thereby limiting prolonged signaling. Similarly, high levels of Notch activation downregulate Numb and Numblike, adaptor proteins that normally inhibit NICD nuclear translocation, establishing a loop to prevent excessive pathway output.

Regulatory Mechanisms

Post-Translational Modifications

Post-translational modifications (PTMs) play a crucial role in regulating the Notch signaling pathway by modulating receptor maturation, ligand binding, intracellular domain stability, and overall signaling output. These modifications, including , ubiquitination, and , fine-tune Notch activity to ensure precise spatiotemporal control during development and . Dysregulation of these PTMs can lead to altered signaling thresholds, impacting cell fate decisions and tissue patterning. O-linked glycosylation is a key PTM that influences Notch receptor-ligand interactions. Protein O-fucosyltransferase 1 (POFUT1) adds O-fucose to specific serine or threonine residues within epidermal growth factor (EGF)-like repeats of the Notch extracellular domain, which is essential for proper receptor folding and trafficking to the cell surface. Subsequent elongation of this O-fucose by fringe glycosyltransferases, such as Lunatic, Manic, and Radical fringe, modifies ligand affinity: it enhances binding to Delta-like ligands while inhibiting interaction with Jagged ligands, thereby establishing directional signaling in tissues. These glycosylation events set a threshold for Notch activation by controlling the efficiency of ligand-induced cleavage, as demonstrated in developmental contexts like Drosophila wing patterning where fringe expression boundaries dictate signaling boundaries. Ubiquitination targets Notch receptors for and lysosomal degradation, preventing excessive signaling. The E3 ubiquitin ligase Nedd4 promotes monoubiquitination and subsequent polyubiquitination of Notch, facilitating its internalization and degradation in a ligand-independent manner, as shown in studies where Nedd4 mutants exhibit ectopic Notch accumulation and disrupted . Similarly, the HECT-type E3 ligase (also known as AIP4) ubiquitinates the Notch intracellular domain (NICD) and full-length receptor, accelerating turnover and suppressing signaling in mammalian cells, particularly in the absence of ligands. These processes maintain low basal Notch activity, ensuring that signaling is only robustly activated upon appropriate presentation. Phosphorylation of the NICD by 8 (CDK8), in complex with C and recruited by the Mastermind co-activator, occurs within the (TAD) and PEST domain, marking NICD for proteasomal degradation via enhanced ubiquitination. This phosphorylation event coordinates transcriptional activation with timely signal termination, as CDK8-mediated modifications reduce NICD from hours to minutes, thereby limiting the duration of target . In developmental settings, such as T-cell differentiation, this regulation establishes signaling thresholds that prevent overactivation and ensure binary cell fate choices. Collectively, these PTMs integrate to calibrate Notch signaling strength, where glycosylation sets activation sensitivity, ubiquitination controls receptor availability, and phosphorylation governs effector persistence, profoundly influencing developmental thresholds like somite boundary formation and lateral inhibition.

Crosstalk with Other Pathways

The Notch signaling pathway engages in extensive crosstalk with other major developmental and homeostatic pathways, enabling context-dependent regulation of cell fate, proliferation, and differentiation. This integration often occurs through direct protein-protein interactions or competition for shared transcriptional co-activators, allowing Notch to modulate or be modulated by pathways such as Wnt, Hedgehog (Hh), and TGF-β. Such interactions are critical in both embryonic development and disease states like cancer, where dysregulated crosstalk can promote tumorigenesis or disrupt tissue homeostasis. Notch and Wnt signaling exhibit in several contexts, where β-catenin, a key Wnt effector, can interact with and stabilize the Notch intracellular domain (NICD) by reducing its ubiquitination, enhancing cooperative activation of target genes like Hes1. In intestinal s, this maintains crypt ; for instance, Wnt-driven β-catenin upregulates Notch ligands such as Dll1, while NICD in turn boosts Wnt responsiveness to balance proliferation and differentiation. In cancer, such as colorectal tumors, hyperactive Notch-Wnt drives aberrant proliferation, with NICD-β-catenin complexes amplifying oncogenic . Similarly, during T-cell development, Notch upregulates TCF1 (a Wnt ), reinforcing β-catenin-mediated . In contrast, Notch often antagonizes signaling via Hes1, a primary Notch transcriptional target, which represses Gli1 expression and thereby inhibits Hh-mediated transcription of downstream genes. This repressive mechanism fine-tunes Hh activity in neural progenitors, where Notch-Hes1 signaling modulates Gli-dependent cell fate decisions in the during embryogenesis. In cancer contexts like and , elevated Hes1 correlates with Gli1 suppression, contributing to tumor heterogeneity and therapeutic resistance; for example, in , Hh pathway activation accelerates Notch-driven oncogenesis when this antagonism is disrupted. TGF-β signaling intersects with Notch through competitive interactions between Smad proteins and NICD for co-activators like p300/CBP, resulting in either synergy or antagonism depending on the cellular context. In synergistic cases, Smad3 associates with NICD to enhance Notch target , such as Hes1 and Hey1, promoting processes like epithelial-to-mesenchymal transition (EMT) in and mammary epithelial cells. Antagonistically, NICD sequesters p300 from Smad3, inhibiting TGF-β-induced growth arrest in contexts like muscle stem cells and certain cancers, where this competition disrupts Smad-mediated transcription. These dynamics are evident in development, where TGF-β-Notch balance regulates differentiation, and in tumorigenesis, such as , where altered co-activator availability exacerbates invasive phenotypes.

Roles in Embryonic Development

Binary Cell Fate Decisions

The Notch signaling pathway is essential for binary cell fate decisions during early embryogenesis, primarily through a mechanism known as , which refines groups of equivalent cells into distinct subtypes by promoting divergence in fate among neighbors. In this process, initially equivalent cells exhibit variation in the expression of Delta-like ligands, which bind to Notch receptors on adjacent cells, triggering a feedback loop that amplifies these differences: cells with higher Delta expression activate Notch in neighbors, leading to repression of Delta in those neighbors and consolidation of the high-Delta state in the signaling cell. This results in a "salt-and-pepper" pattern where isolated singlets or small clusters adopt the primary fate (e.g., neuronal), while surrounding cells adopt the secondary fate (e.g., maintenance), ensuring balanced without overproduction of one type. A classic example occurs in sensory organ development, where the sensory organ precursor (SOP) cell undergoes asymmetric divisions to generate diverse cell types in the external sensory organ. During these divisions, the adaptor protein Numb localizes asymmetrically to one daughter cell, inhibiting Notch signaling specifically in that cell by promoting the endocytosis and degradation of the Notch intracellular domain, thereby allowing Delta expression and adoption of the neuronal fate in the Numb-inherited cell while the sibling receives active Notch signaling and differentiates into a sheath or socket cell. This binary outcome is reinforced by cell-cell interactions, where the Numb-positive cell signals via Delta to suppress neuronal fate in its sibling through Notch activation. In mammals, analogous mechanisms operate in neural progenitors, where Notch-mediated balances the production of neurons and maintenance of the progenitor pool during cortical . Progenitors with low Notch activity (due to higher Delta expression) exit the to become neurons, while activating Notch in neighbors sustains their proliferative state, preventing excessive and ensuring proper layering of the neural tube.00153-X) This process mirrors the system but involves mammalian Notch1-4 receptors and Delta-like ligands, with disruptions leading to precocious neuronal differentiation. Conceptually, the mathematical basis of this feedback amplification relies on a bistable system where mutual inhibition between Delta and Notch creates a switch-like response to initial fluctuations, such that small differences in levels are robustly amplified into stable, opposing fates across the cell , as modeled in early theoretical frameworks of intercellular signaling dynamics.

Somitogenesis and Segmentation

Somitogenesis in vertebrates involves the sequential formation of somites from the presomitic mesoderm (PSM), which establishes the segmented body axis including the vertebrae and skeletal muscles. The Notch signaling pathway plays a pivotal role in this process through its involvement in the segmentation clock, a molecular oscillator that generates periodic signals to coordinate somite boundaries. Central to this clock is the cyclic expression of the basic helix-loop-helix (bHLH) transcription factor Hes7 in the PSM, where its mRNA and protein levels oscillate with a period of approximately 2 hours in mice. This oscillation arises from a negative feedback loop integrated with Notch signaling: Hes7 represses its own transcription and that of the Notch Delta-like 1 (Dll1), while Dll1 activates Notch receptors in neighboring cells, leading to the release of the Notch intracellular domain (NICD). NICD then translocates to the nucleus and, in complex with RBPJ, induces Hes7 expression, thereby sustaining the oscillatory dynamics across PSM cells. Synchronization of these oscillations among cells is facilitated by Dll1-mediated lateral inhibition and modulation by Lunatic fringe (Lfng), which oscillates under Hes7 control and alters Notch-Dll1 affinity to propagate waves of activity. Phase differences in Hes7 expression emerge along the PSM, with posterior cells leading in phase relative to anterior ones, ensuring progressive maturation. The segmentation clock interacts with a wavefront of maturation signals to determine somite boundary positions. A posterior-to-anterior of (FGF) signaling, primarily from FGF4 and FGF8, defines this by repressing somite maturation in the posterior PSM while allowing it anteriorly. FGF signaling acts upstream of the Notch pathway, maintaining oscillatory by influencing Hes7 levels and preventing premature differentiation; inhibition of FGF leads to disrupted clock oscillations and irregular . When the oscillating clock meets the advancing in the anterior PSM, Notch activity stabilizes cell fate decisions, triggering boundary formation through downstream effectors like Mesp2. This clock-and-wavefront model ensures precise spatiotemporal control, with each cycle producing one pair of every 2 hours in mice. Disruptions in the Notch pathway during somitogenesis lead to severe segmentation defects, exemplified by spondylocostal dysostosis (SCDO), a group of autosomal recessive disorders characterized by multiple vertebral malformations and rib anomalies. Mutations in genes encoding Notch components, such as DLL3 (causing SCDO1), MESP2 (SCDO2), (SCDO3), and HES7 (SCDO4), impair oscillatory signaling and boundary formation, resulting in fused or irregular .60803-9)00372-4) For instance, DLL3 mutations abolish cyclic expression in the PSM, leading to disorganized vertebral segmentation without affecting initial somite formation. Similarly, HES7 loss disrupts the feedback loop, causing widespread axial defects in both mice and humans. These findings underscore the Notch pathway's essential, non-redundant role in axial patterning.

Neural and Epidermal Patterning

In the developing , Notch signaling plays a pivotal role in refining proneural clusters through mediated by Delta ligands. Within these clusters of ectodermal cells competent to adopt neural fates, stochastic expression of Delta activates Notch in neighboring cells, repressing neuronal differentiation genes such as proneural basic helix-loop-helix (bHLH) factors like Neurogenin or Ash1. This feedback loop amplifies Delta expression in the signal-sending cell, promoting its neuronal commitment while inhibiting it in adjacent cells, thereby selecting spaced single neuroblasts from the cluster. Dynamic facilitate intermittent Delta-Notch contacts, ensuring gradual pattern refinement and uniform spacing of neuroblasts across the proneural field.00296-0) Notch signaling, modulated by Fringe glycosyltransferases, further contributes to establishing the boundary between neural and epidermal during early formation. Fringe modifies Notch receptors by adding O-fucose-linked GlcNAc, enhancing Notch activation by Delta-like ligands while inhibiting activation by /Serrate ligands, thus creating directional signaling biases at tissue interfaces. In the presumptive border, differential Fringe expression restricts Notch activity to delineate neural from non-neural (epidermal) territories, preventing ectopic neural induction in epidermal regions and ensuring proper ectodermal patterning. This mechanism is conserved across vertebrates, where Fringe boundaries align with Notch-dependent patterning centers in the . In cranial placode development, Notch signaling regulates the balance between sensory epithelial and neuronal fates in precursors destined for sensory structures such as the and . Through , activated Notch in prosensory cells suppresses neuronal differentiation in neighbors, promoting uniform prosensory domain formation before subsequent . This process involves Notch-dependent upregulation of prosensory genes like , ensuring coordinated development of sensory organs from placodal . Disruption of Notch leads to overproduction of neurons at the expense of sensory epithelia, highlighting its role in placode maturation. Genetic models in zebrafish and mice reveal delamination defects underscoring Notch's role in neural and epidermal patterning. In zebrafish mind bomb mutants, which impair Delta ubiquitination and thus Notch activation, excessive neuronal precursors delaminate prematurely from the neuroepithelium, leading to disorganized spinal cord patterning and depletion of progenitors. Similarly, in mouse embryos with conditional inactivation of Notch1 or RBP-Jκ in the ectoderm, neural precursors exhibit aberrant delamination and increased neurogenesis, resulting in thinner epidermal layers and disrupted neural tube boundaries. These defects confirm Notch's essential function in coordinating delamination timing to maintain ectodermal organization.

Roles in Organ Development

Cardiovascular System Formation

The Notch signaling pathway plays a critical role in embryonic cardiovascular development by regulating key processes such as endocardial cushion formation, outflow tract septation, and vascular specification, ensuring proper heart septation, valve morphogenesis, and vessel patterning. In the atrioventricular (AV) canal, Notch1 activation in endocardial cells is essential for initiating epithelial-to-mesenchymal transition (EMT), which drives the formation of endocardial cushions that contribute to AV valve development. Targeted inactivation of Notch1 or its transcriptional mediator RBPJκ results in severely hypoplastic cushions due to impaired EMT, highlighting Notch1's non-redundant function in this region. In the outflow tract (OFT), Notch2 and RBPJ cooperate to facilitate proper alignment and septation, preventing congenital defects like double-outlet right ventricle (DORV) and . Conditional inactivation of RBPJ in the second heart field or cardiac using Cre drivers such as Islet1-Cre or /Wnt1-Cre disrupts OFT by reducing expression of downstream effectors like Fgf8 and Bmp4, which are necessary for migration and EMT in cushion formation. Notch2 is prominently expressed in the pharyngeal and -derived cells surrounding the arteries, supporting its role in coordinating tissue interactions for OFT alignment. Notch signaling also governs arterial versus venous fate decisions during vessel specification, particularly through DLL4-Notch interactions in endothelial tip cells during sprouting . DLL4, expressed in tip cells, activates Notch receptors in adjacent stalk cells to suppress excessive branching and promote arterial identity while inhibiting venous specification, thereby balancing vascular network formation. Disruptions in this pathway, such as DLL4 mutations, lead to aberrant tip cell overproduction and defective artery-vein patterning. Mutations in NOTCH1 are associated with congenital heart defects, including (BAV) and (TOF), underscoring the pathway's clinical relevance. Pathogenic NOTCH1 variants explain approximately 2% of familial BAV cases and contribute to left obstructions like TOF by impairing valve cusp formation and septation. In mouse models, compound Notch1 and Gata5 mutations recapitulate BAV with high , demonstrating how reduced Notch signaling disrupts endocardial cushion maturation in the OFT.

Endocrine and Skeletal Differentiation

In pancreatic development, Notch signaling plays a critical role in regulating endocrine cell differentiation, particularly for beta cells, by maintaining multipotent progenitors in an undifferentiated state. Activation of Notch receptors leads to the transcription of Hes1, a downstream effector that directly represses the pro-endocrine Neurogenin 3 (Ngn3) through binding to silencer sites near its transcription start site. This inhibition prevents premature endocrine specification, ensuring a temporal wave of Ngn3 expression around embryonic day 15.5 in mice, which is essential for the sequential generation of , delta, and PP cells from progenitors. Relief of Notch-mediated repression occurs via mechanisms, where stochastic Ngn3 expression in a subset of progenitors downregulates Notch activity in those cells, allowing full endocrine commitment while neighbors remain progenitors. In the intestinal crypt-villus axis, Notch signaling sustains the pool of proliferative progenitors during , directing cell fate toward absorptive lineages. High Notch activity in crypt base columnar stem cells (marked by ) and transit-amplifying cells promotes self-renewal and proliferation through targets like Hes1, which suppress secretory fate determinants such as Atoh1. As progenitors migrate upward along the villus, diminishing Notch signaling enables differentiation into enterocytes, while sustained activity in select cells inhibits goblet, enteroendocrine, and specification. This gradient ensures balanced epithelial renewal, with ligands like Dll1 and Dll4 from s reinforcing Notch in adjacent stem cells to prevent ectopic secretory differentiation. Notch signaling, particularly through the ligand Jagged1 (JAG1), modulates skeletal differentiation by balancing and lineages to support formation. JAG1 maintains the osteoprogenitor pool by inhibiting excessive differentiation into mature , as evidenced by increased trabecular mass and osteocalcin-positive cells in JAG1-deficient models (e.g., Prx1-Cre deletion). This regulation indirectly influences , with JAG1 loss leading to elevated markers like CTX and larger , despite reduced numbers in some regions, due to altered expression from osteolineage cells. In , Notch receptors (e.g., Notch1 and Notch2) exhibit context-dependent effects: Notch1 suppresses osteoclastogenesis, while Notch2 enhances it, ensuring during . Mutations in JAG1, encoding a key Notch ligand, underlie , disrupting endocrine-related structures like and contributing to skeletal anomalies. Haploinsufficiency of JAG1 impairs Notch signaling, leading to bile duct paucity in 80-90% of cases through defective ductal plate remodeling and progenitor differentiation in the liver. Cardiovascular manifestations, such as pulmonary stenosis in over 90% of patients, arise from similar Notch-dependent defects in endocardial cushion formation and outflow tract septation, highlighting JAG1's role in mesenchymal-endothelial interactions. While skeletal features like butterfly vertebrae occur less frequently, they stem from JAG1's influence on somitic and vertebral development via Notch-mediated cell fate decisions.

Gastrointestinal and Pancreatic Morphogenesis

The Notch signaling pathway plays a critical role in anterior-posterior (A-P) patterning of the definitive during early gastrointestinal development, where it interacts with (FGF) signaling to establish regional identities. In this process, Notch activation in endodermal progenitors promotes anterior specification while suppressing posterior fates, ensuring proper gut tube regionalization; this interplay is evident in models where combined Wnt and Notch modulation directs A-P axis formation in the . Disruption of this Notch-FGF coordination can lead to misspecification of endodermal domains, highlighting its essential function in initial gut tube . In intestinal villus morphogenesis, Notch signaling directs the differentiation of epithelial progenitors toward absorptive enterocytes rather than secretory lineages, such as goblet or Paneth cells. Activation of Notch suppresses Math1 (Atoh1) expression, thereby favoring enterocyte fate and maintaining the balance required for villus architecture; conditional inhibition of Notch in mouse intestinal epithelium results in a complete conversion of absorptive cells to secretory types, disrupting villus formation. Models of Notch loss, such as deletion of Notch pathway components like Pofut1 or Rbp-j, lead to goblet cell hyperplasia and hyperplastic crypts due to unchecked secretory differentiation and altered proliferation dynamics.00760-8/fulltext) For endocrine pancreas development, Notch signaling exerts stepwise inhibition on multipotent progenitors to regulate the timely emergence of , and other islet cell types. Initially, sustained Notch activity in Pdx1-positive progenitors represses neurogenin3 (Ngn3) expression, preventing premature endocrine differentiation and maintaining an undifferentiated pool; subsequent oscillatory or transient Notch inhibition then allows waves of Ngn3 activation, enabling sequential specification of endocrine subtypes. In mouse models, loss of Notch function, such as through conditional of Notch1 or its effectors, triggers early and excessive endocrine differentiation but impairs overall , contributing to reduced beta-cell mass and glucose intolerance resembling diabetic states.

Roles in Adult Physiology

Tissue Homeostasis and Stem Cell Maintenance

The Notch signaling pathway plays a crucial role in maintaining tissue in adult epithelia by regulating self-renewal, proliferation, and differentiation, ensuring balanced renewal without excessive expansion or depletion. In the , Notch activity sustains LGR5+ base columnar through interaction with the RBPJ, preventing premature differentiation into secretory lineages such as goblet cells. Inhibition of Notch signaling, via gamma-secretase blockers, rapidly converts proliferative progenitors and LGR5+ cells into goblet cells, leading to loss of pools and impaired regeneration, as demonstrated in models. This RBPJ-dependent mechanism integrates with Wnt signaling to fine-tune the balance between maintenance and lineage commitment, supporting continuous epithelial turnover. In the liver, Notch signaling facilitates regeneration and biliary repair following by directing hepatic cells toward cholangiocyte fates. After , such as partial hepatectomy or toxin-induced , Notch-RBPJ activation in populations promotes biliary tubulogenesis and restores intrahepatic integrity, preventing aberrant hepatocyte-to-cholangiocyte . Studies in conditional mice show that disrupting Notch2 or RBPJ in hepatoblasts impairs biliary remodeling, resulting in defective duct formation and , underscoring its essential role in parenchymal . This pathway's coordination with other signals, like Wnt, ensures precise spatial patterning during repair, maintaining liver architecture. Within the skin, Notch enforces differentiation in the interfollicular epidermis, restricting proliferation to basal keratinocytes and promoting suprabasal commitment to stratified layers. Conditional deletion of Notch1 in murine keratinocytes leads to epidermal hyperplasia, with increased Ki67+ proliferating cells and disrupted expression of differentiation markers like involucrin and loricrin, highlighting its tumor-suppressive function in homeostasis. Notch signaling achieves this by activating p21 and repressing , thereby coupling exit to barrier formation and preventing dysregulated growth. In hair follicles, Notch signaling supports cycling by promoting the anagen growth phase through regulation of bulge stem cell activation and matrix cell differentiation. Activation of Notch1 in follicular progenitors enhances proliferation during early anagen, ensuring proper shaft and sheath formation, while its absence disrupts bulb matrix integrity and delays cycle progression. This temporal control, mediated by ligands like Jagged1, integrates with BMP and Wnt pathways to synchronize quiescence in telogen and expansion in anagen, preserving follicle renewal throughout adulthood.

Hematopoiesis and Immune Regulation

In adult hematopoiesis, Notch signaling plays a pivotal role in thymic T-cell lineage commitment, particularly through Notch1, which is essential for directing early hematopoietic progenitors toward the T-cell fate and preventing alternative lineages such as B-cell or myeloid differentiation. Conditional inactivation of Notch1 in hematopoietic progenitors results in a complete block of T-cell development at the early double-negative (DN1) stage, leading to the accumulation of immature progenitors that divert to B-cell or dendritic cell lineages, thereby underscoring Notch1's non-redundant function in specifying T-cell identity. Progression to the double-positive (DP) stage, where thymocytes express both CD4 and CD8, further relies on sustained Notch1 signaling, which promotes survival, proliferation, and successful β-selection at the DN3 stage via pre-TCR signaling integration; disruption here impairs VDJβ rearrangement and DP maturation, highlighting Notch1's regulatory influence on TCR-mediated checkpoints. Notch signaling also governs B-cell maturation in the , with Notch2 and its Jagged1 (JAG1) being critical for the development and positioning of marginal zone B (MZB) cells, a subset specialized in rapid responses to blood-borne antigens. Notch2 is preferentially expressed in mature B cells, and its conditional deletion abolishes MZB cell generation while sparing follicular B cells, demonstrating that Notch2 signaling, mediated by interactions with stromal JAG1 in the splenic marginal zone, instructs transitional B cells to adopt the MZB fate through RBP-J-dependent transcriptional programs that upregulate MZB-specific genes like Cd21 and Aicda. JAG1 expression in splenic endothelial and mesenchymal cells provides the positional cues for MZB localization and retention, as its absence disrupts MZB homeostasis and leads to impaired against T-independent antigens. In innate immune regulation, Notch signaling modulates macrophage polarization, influencing the balance between pro-inflammatory M1 and anti-inflammatory phenotypes during immune responses. Activation of Notch1 or Notch2 promotes M1 polarization by enhancing activity and production such as TNF-α and IL-12, while suppressing M2 markers like Arg1 and IL-10; for instance, in tumor microenvironments, reduced Notch signaling in tumor-associated favors M2-like states that support tumor progression, whereas forced Notch shifts them toward antitumor M1 responses. This bidirectional control allows Notch to fine-tune macrophage function in and tissue repair, with ligand-specific effects—such as DLL1 favoring M1—further dictating phenotypic outcomes. Defects in Notch signaling disrupt hematopoietic and immune , often resulting in or . Loss-of-function mutations in NOTCH1, as modeled by conditional knockouts, cause severe T-cell deficiency akin to combined , with absent thymic development and increased susceptibility to infections due to impaired adaptive immunity. Conversely, dysregulated hyperactive Notch signaling can precipitate by altering B-cell tolerance and promoting lymphoproliferation; for example, aberrant TCR-Notch crosstalk in T cells drives autoreactive responses and immune dysregulation, contributing to conditions like systemic through failed negative selection and excessive signaling.

Roles in Disease

Developmental Disorders

Mutations in components of the Notch signaling pathway underlie several monogenic developmental disorders, primarily through loss-of-function or gain-of-function alterations that disrupt embryonic patterning, vascular development, and somitogenesis. These conditions manifest as multisystem anomalies, with inheritance patterns typically autosomal dominant for receptor or haploinsufficiency and autosomal recessive for modulator defects. Alagille syndrome (ALGS) is an autosomal dominant disorder caused by heterozygous mutations in JAG1 (94% of cases) or NOTCH2 (approximately 2-3% of cases), leading to of the Notch ligand or receptor essential for and cardiovascular development. Clinical hallmarks include paucity of resulting in neonatal and progressive liver , alongside congenital heart defects such as peripheral pulmonary (affecting up to 67% of patients) and . Other features encompass butterfly vertebral anomalies, posterior embryotoxon, and characteristic facial dysmorphism with a broad forehead and pointed chin. The syndrome exhibits variable expressivity and reduced , with about 60% of cases arising de novo; prevalence is estimated at 1 in 30,000 to 50,000 live births. Adams-Oliver syndrome (AOS) is a rare autosomal dominant or recessive disorder caused by heterozygous loss-of-function in NOTCH1 (AOS5 subtype, ~15-20% of dominant cases), DLL4, or modifiers like EOGT, disrupting Notch-mediated vascular and somitic development. Patients present with (scalp/skin defects at birth), terminal transverse limb malformations (e.g., , ), and cardiovascular anomalies such as septal defects or in up to 20% of cases. Additional features may include cutis marmorata telangiectatica congenita and variable neurological involvement. Inheritance shows incomplete penetrance; prevalence is less than 1 in 1,000,000 live births. Spondylocostal dysostosis (SCD) refers to a spectrum of autosomal recessive skeletal disorders featuring defective vertebral segmentation due to disrupted oscillatory Notch signaling in the presomitic mesoderm. SCD type 1 (SCDO1) results from biallelic mutations in DLL3, a Delta-like Notch ligand that inhibits adjacent somite formation, while SCD type 3 (SCDO3) arises from mutations in LFNG, encoding a β-1,3-N-acetylglucosaminyltransferase that O-fucosylates and modifies Notch receptors to regulate their activation. Patients present with short-trunk dwarfism, multiple hemivertebrae and vertebral fusions spanning the cervical to sacral regions, and rib malformations including fusions or deletions, which can impair respiratory function and cause thoracic insufficiency. Inheritance is strictly autosomal recessive with high consanguinity in reported families; the disorder is rare, with exact prevalence unknown but segmentation defects overall occurring in 0.5-1 per 1,000 live births and SCD subtypes far less common.

Cancer Pathogenesis

The Notch signaling pathway exhibits a in , acting as an in certain hematologic and solid tumors while functioning as a tumor suppressor in others, with context-dependent outcomes influenced by cellular microenvironment and genetic alterations. In (T-ALL), activating mutations in NOTCH1 occur in over 50% of cases, primarily affecting the heterodimerization domain and PEST domain, leading to ligand-independent signaling that promotes leukemic cell proliferation and survival by sustaining oncogenes like and inhibiting . These mutations, first identified in seminal studies, drive clonal expansion and are associated with distinct T-ALL subtypes, underscoring Notch's oncogenic dominance in lymphoid malignancies. In solid tumors, Notch often promotes tumorigenesis through ligand overexpression and epithelial-mesenchymal transition (EMT). JAG1 overexpression is frequently observed in , where it activates Notch signaling to induce EMT, enhancing invasiveness and , particularly in hypoxic tumor niches that amplify this effect via hypoxia-inducible factors. Similarly, in non-small cell lung cancer (NSCLC), elevated JAG1 levels correlate with EMT progression, tumor cell migration, and poor prognosis, as JAG1-Notch interactions upregulate Slug and other transcription factors that disrupt epithelial integrity. Conversely, Notch exerts a tumor-suppressive function in (SCC) by promoting differentiation and inhibiting proliferation; loss-of-function mutations in NOTCH1 and NOTCH2, present in up to 75% of cutaneous SCC cases, lead to and tumor progression, highlighting its role in maintaining epidermal . Notch signaling integrates with other pathways in the (TME), modulating immune evasion and stromal interactions. Crosstalk with EGFR amplifies oncogenic signaling in and cancers, where EGFR activation upregulates JAG1 to sustain Notch-mediated EMT and resistance to therapy. Similarly, PI3K/AKT pathway hyperactivation intersects with Notch in the TME, promoting and immunosuppressive phenotypes in various carcinomas. Recent advances (2023-2025) reveal Notch's tumor-suppressive role in neuroendocrine tumors, where its inhibits neuroendocrine differentiation and alters the immune landscape, as seen in and small cell cancers, offering potential for γ-secretase inhibitors to reverse aggressive phenotypes. In , aberrant Notch sustains stem cell heterogeneity and therapy resistance, with 2024 studies showing upregulated Notch and synaptic genes in infiltrated tissue, contributing to recurrence. For hepatocellular carcinoma (HCC), recent insights (2023-2025) emphasize Notch's promotion of proliferation and , with activated signaling in 30% of cases linked to poor prognosis and , prompting targeted inhibition strategies.

Neurodegenerative and Cardiovascular Diseases

The Notch signaling pathway plays a critical role in neurodegenerative diseases, particularly through disruptions in gamma-secretase-mediated processing. In familial (fAD), mutations in (PSEN1), the catalytic subunit of the gamma-secretase complex, impair the cleavage of the Notch receptor, reducing the release of the Notch intracellular domain (NICD) and thereby diminishing Notch signaling. This reduction in Notch activity leads to premature in human models, as observed in iPSC-derived cortical cultures and cerebral organoids from fAD patients carrying PSEN1 mutations such as int4del and Y115H, where NICD levels are significantly lowered (p=0.0047). Such impairments highlight a mechanistic overlap between altered amyloid precursor protein (APP) processing and defective Notch signaling, contributing to early-onset neurodegeneration without uniformly affecting all PSEN1 variants. Cerebral autosomal dominant arteriopathy with subcortical infarcts and (CADASIL), caused by NOTCH3 mutations, exemplifies how vascular defects extend to neurodegeneration. These mutations, predominantly missense variants in the epidermal growth factor-like repeats (EGFr) of NOTCH3 (e.g., R1006C, R133C), result in protein misfolding, aggregation, and degeneration of vascular cells (VSMCs), leading to small vessel disease and chronic cerebral hypoperfusion. This vascular pathology manifests as progressive cognitive decline starting around age 35, with approximately 75% of patients developing characterized by and memory impairment, alongside white matter hyperintensities and lacunar infarcts on . The neurodegenerative extension arises from ischemic damage and impaired blood-brain barrier integrity, linking NOTCH3 dysfunction to subcortical and overlapping features with pathology, such as amyloid-β accumulation. In cardiovascular diseases, Notch signaling influences by modulating endothelial and plaque stability. Activation of Notch1 in endothelial cells, often triggered by or bone morphogenetic protein receptor type 2 (BMPR2), maintains barrier function and suppresses pro-inflammatory adhesion molecules like and , thereby limiting recruitment under atherogenic conditions such as or TNF-α exposure. However, dysregulated Notch signaling, particularly via the Dll4/Notch1 axis, promotes M1 polarization and activation, elevating cytokines like IL-6 and TNF-α, which exacerbate plaque and instability; inhibition with gamma-secretase blockers like DAPT reduces lesion progression in ApoE−/− mouse models. Additionally, Notch signaling supports fibrous cap formation by regulating cell differentiation, preventing plaque rupture. Notch signaling also contributes to stroke and vascular cognitive impairment (VCI) through vascular integrity and post-ischemic repair. In ischemic models, Notch3 deficiency in VSMCs increases infarct volume by approximately twofold (P<0.01) and mortality by 60%, as seen in Notch3 knockout mice subjected to middle cerebral artery occlusion, due to impaired and expanded cerebral blood flow deficits. This heightened stroke burden stems from downregulated genes for and vascular tone, leading to more peri-infarct depolarizations (6.0 ± 2.5 vs. 2.9 ± 2.5 PIDs/h, P<0.05). In VCI models, including , aberrant Notch signaling—such as from NOTCH3 mutations—disrupts endothelial differentiation and blood-brain barrier maintenance, promoting chronic hypoperfusion, amyloid-β/ pathology, and cognitive deficits akin to post-stroke . Rescue experiments with SMC-specific human NOTCH3 expression confirm its protective role against ischemic damage.

Therapeutics and Synthetic Applications

Notch Inhibitors and Modulators

The Notch signaling pathway has been targeted therapeutically through pharmacological inhibition, primarily via gamma-secretase inhibitors (GSIs) that prevent the cleavage and activation of Notch receptors. GSIs, such as RO4929097 (also known as R04929097), block the gamma-secretase complex responsible for intramembrane of Notch, thereby suppressing downstream signaling. In preclinical models of (T-ALL), where activating Notch1 mutations drive oncogenesis, RO4929097 demonstrated potent antitumor activity by inducing in Notch-dependent cell lines. Clinical trials have evaluated RO4929097 in relapsed or refractory T-ALL; a phase I study in pediatric patients with advanced solid tumors and leukemias, including T-ALL, established a maximum tolerated dose of 1.56 mg/m² daily on a 3-days-on/4-days-off schedule, with preliminary evidence of disease stabilization but limited complete responses due to dose-limiting toxicities like and . The phase II trial in T-ALL showed no objective responses but stable disease in 19% of patients, indicating limited monotherapy activity and highlighting the need for combination strategies to overcome resistance. Monoclonal antibodies targeting Notch ligands, particularly delta-like ligand 4 (DLL4), represent another class of inhibitors aimed at disrupting ligand-receptor interactions in tumor angiogenesis and cancer stem cell maintenance. Demcizumab (OMP-21M18), a humanized anti-DLL4 antibody, binds to DLL4 on endothelial and tumor cells, inhibiting Notch activation and promoting non-productive . In phase I dose-escalation trials for advanced solid tumors, including ovarian, pancreatic, and non-small cell lung cancers, demcizumab at doses up to 5 mg/kg weekly was generally well-tolerated, with grade 3/4 adverse events primarily limited to and , and demonstrated antitumor activity through disease stabilization in 40% of patients and partial responses in select cases. A phase Ib study combining demcizumab with and in platinum-resistant reported an objective response rate of 31%, superior to chemotherapy alone, though higher doses led to hemorrhagic toxicities due to vascular disruption. The phase II YOSEMITE trial in pancreatic ductal did not meet its primary endpoint of improved , with median PFS of 5.5 months in both demcizumab and arms, leading to discontinuation of further development as of 2017. Broad inhibition of Notch signaling by GSIs and ligand-targeting antibodies carries significant safety concerns, particularly gastrointestinal toxicities arising from disrupted intestinal . Systemic GSI administration induces goblet cell in the intestinal , where Notch normally suppresses secretory cell differentiation; this leads to increased production, crypt dilation, and mucosal , as observed in preclinical models and early trials. For instance, RO4929097 trials reported dose-limiting and in up to 50% of patients, attributed to goblet cell confirmed via endoscopic biopsies. Similarly, DLL4 inhibitors like demcizumab have been associated with mild gastrointestinal effects, though less severe than GSIs, due to more targeted endothelial disruption. These on-target toxicities necessitate intermittent dosing schedules or combination with supportive agents to mitigate risks while preserving therapeutic efficacy. In contrast, Notch agonists have emerged for regenerative applications, leveraging pathway activation to promote tissue repair and differentiation. Soluble Jagged1 (JAG1), a recombinant form of the Notch , mimics juxtacrine signaling to stimulate cells without requiring cell-cell contact. Preclinical studies in cartilage regeneration demonstrated that intraoperative delivery of soluble JAG1 to damaged articular surfaces in rabbit models enhanced proliferation and deposition, restoring tissue architecture comparable to uninjured controls. In hematopoietic contexts, engineered soluble JAG1 variants have driven T-cell development from progenitors, suggesting utility in and bone marrow reconstitution. For and vascular regeneration, soluble JAG1 hydrogels promote endothelial sprouting and recruitment, accelerating tissue vascularization in diabetic mouse models of repair. These agonists highlight a shift toward pathway modulation for non-oncologic therapies, with ongoing efforts to optimize and specificity.

Engineered Notch Systems

Engineered Notch systems, particularly synthetic Notch (synNotch) receptors, represent a modular platform for reprogramming cellular responses to specific extracellular cues, decoupling ligand recognition from canonical Notch intracellular domain release to enable customizable transcriptional outputs. In synNotch design, the extracellular domain of the Notch receptor is replaced with an antibody-derived (scFv) that binds a user-defined , while the transmembrane and intracellular domains retain the native Notch cleavage machinery, including ADAM10 and γ-secretase sites, leading to ligand-inducible release of a transcriptional regulator fused to the intracellular portion. This allows precise control over in response to surface-bound antigens, functioning in diverse cell types such as neurons, fibroblasts, and T cells without relying on endogenous Notch pathways. Integration of synNotch receptors with chimeric receptor () T-cell therapy has advanced in solid tumors by introducing logic-gated responses that mitigate off-tumor . In these circuits, synNotch activation by a induces expression of a targeting a secondary , ensuring T-cell only occurs in cells expressing both markers, thus enhancing specificity against heterogeneous tumors like . Preclinical studies in models of ovarian and cancers demonstrated that synNotch- T cells achieved superior tumor clearance and persistence compared to conventional CAR-T, with reduced exhaustion and . As of 2025, synNotch -T therapies have advanced with improved multi- sensing for solid tumors like , enhancing tumor clearance in preclinical models while minimizing off-tumor effects. Recent optimizations, including orthogonal synNotch variants, have further improved multi- sensing for broader solid tumor applications. Mechanical Notch sensors extend synNotch technology to detect and respond to physical forces, enabling force-responsive circuits for studying mechanotransduction or mechanically sensitive cells. These tension-tuned synNotch receptors incorporate force-sensitive linkers or modified extracellular domains that activate signaling only upon application of tensile forces, such as those from cell-matrix adhesions or intercellular pulling, converting mechanical inputs into transcriptional outputs with tunable sensitivity thresholds around 1-10 pN. In 2023 advancements, such sensors were used to program fibroblasts to express osteogenic under , mimicking . By 2025, fully protein-based variants integrated aptamer-derived mechanoreceptors for cell-specific force detection, enhancing precision in dynamic environments. Applications of engineered Notch systems in and leverage their programmability to direct differentiation and orchestrate multicellular assembly. SynNotch-modified mesenchymal stem cells have been engineered to sense biomaterial-presented cues, such as collagen-bound ligands, triggering secretion of growth factors for vascular network formation in scaffolds, promoting in diabetic mouse models. In regenerative contexts, these systems facilitate patterned tissue ; for instance, synNotch circuits in human induced pluripotent stem cell-derived progenitors enable sequential activation of differentiation cascades upon exposure to spatially defined ligands, yielding organized intestinal organoids with improved functionality. Recent 2024 developments include material-synNotch interfaces for implant-guided regeneration, where titanium scaffolds coated with synNotch ligands direct osteoblast recruitment and repair , demonstrating enhanced integration over passive scaffolds.

Mathematical and Computational Modeling

Kinetic Models of Signaling

Kinetic models of Notch signaling primarily employ ordinary differential equations (ODEs) to capture the temporal dynamics of receptor activation, intracellular domain release, and downstream effector accumulation, providing insights into signal duration and amplitude at the single-cell level. These models simplify the pathway by focusing on core biochemical reactions, such as ligand-induced receptor cleavage and nuclear translocation of the Notch intracellular domain (NICD), while incorporating loops that regulate signaling strength. Seminal formulations emphasize mass-action kinetics to describe NICD production and degradation, enabling predictions of how transient exposure translates into sustained or pulsatile nuclear activity. A foundational kinetic model for NICD dynamics is given by the ODE: d[NICD]dt=kcleavage[LigandReceptor]kdegradation[NICD],\frac{d[\mathrm{NICD}]}{dt} = k_{\mathrm{cleavage}} \cdot [\mathrm{Ligand-Receptor}] - k_{\mathrm{degradation}} \cdot [\mathrm{NICD}], where kcleavagek_{\mathrm{cleavage}} represents the rate of proteolytic release following ligand binding, [LigandReceptor][\mathrm{Ligand-Receptor}] denotes the activated receptor complex, and kdegradationk_{\mathrm{degradation}} accounts for NICD proteasomal breakdown. This equation highlights the balance between signal generation and decay, with typical half-lives for NICD on the order of 1-2 hours, ensuring transient signaling unless reinforced by feedback. Extensions incorporate inhibitory modifications, such as by Lunatic fringe (Lfng), which reduces cleavage efficiency via Hill-type inhibition, thereby modulating signal duration in contexts like somitogenesis. To address oscillatory behaviors, delay differential equations (DDEs) extend these models by accounting for time lags in transcription and translation, particularly for downstream targets like Hes1. A classic DDE for Hes1 autorepression is: d[Hes1]dt=a1+([Hes1](tτ)K)nb[Hes1],\frac{d[\mathrm{Hes1}]}{dt} = \frac{a}{1 + \left( \frac{[\mathrm{Hes1}](t - \tau)}{K} \right)^n} - b \cdot [\mathrm{Hes1}], where aa is the maximal production rate, τ\tau is the total delay (typically 20-30 minutes for transcription/translation), KK is the repression threshold, nn is the Hill coefficient (often 2-4 for cooperative binding), and bb is the degradation rate. This formulation predicts sustained oscillations with periods of 2-3 hours, as observed in presomitic during somitogenesis, where Notch-driven Hes7 pulses synchronize segmentation clocks across cells. Such delays arise from the stepwise nature of and are crucial for preventing stable repression, allowing cyclic activation. Parameter sensitivity analyses reveal that cleavage rates profoundly influence signal duration and oscillatory fidelity; for instance, variations in kcleavagek_{\mathrm{cleavage}} by 20-50% can extend or shorten NICD pulses, altering the phase and amplitude of Hes oscillations and thus boundary formation timing. In one model, the Notch pathway exhibited high sensitivity to Lfng-mediated cleavage inhibition, with perturbations shifting oscillation periods by up to 10%, underscoring the pathway's robustness yet tunability to parameter changes. Degradation rates for NICD and Hes1 similarly affect peak levels, with faster decay promoting higher-frequency but lower-amplitude cycles. These kinetic models have been validated against live-cell imaging data, where fluorescent reporters track real-time NICD nuclear entry and Hes1/Hes7 oscillations. For example, quantitative imaging in mouse presomitic mesoderm confirmed DDE-predicted periods of ~2 hours for Hes1 pulses, with variations matching simulated noise in delayed models, thereby supporting the role of transcriptional delays . Such alignments demonstrate the predictive power of these simplified kinetics for dissecting temporal control in Notch-mediated processes.

Systems Biology Approaches

Systems biology approaches integrate the Notch signaling pathway into multi-scale computational frameworks to model its interactions with other pathways, enabling predictions of emergent tissue-level phenomena such as cell patterning and disease progression. These methods emphasize holistic network dynamics rather than isolated kinetics, incorporating Notch as a key regulator in regulatory graphs and spatial simulations. networks represent Notch signaling as a discrete switch within regulatory graphs, facilitating the analysis of cell fate decisions through binary states of or inhibition. In these models, Notch acts as a feedback element in motifs, where ligand-receptor interactions propagate signals across cells to stabilize heterogeneous fates, such as in or hematopoiesis. For instance, logical modeling frameworks applied to T cell differentiation delineate a regulatory graph where Notch1 , influenced by Delta-like ligands, contributes to T cell commitment. These approaches predict bistable outcomes in fate specification, highlighting Notch's role in amplifying small initial differences into robust population-level patterns. Spatial agent-based models extend these networks by simulating individual cell behaviors in a tissue context, particularly for patterning where Notch-Dll4 signaling coordinates endothelial cell . In such models, cells migrate and interact via diffusive VEGF gradients, with Notch stochastically selecting tip cells that express high Dll4 to inhibit neighboring cells from , thus forming ordered vascular networks. A spatialized of Notch in demonstrates how rapid endothelial cell rearrangements under conditions, like in tumors, disrupt this patterning, leading to chaotic vessel formation. Complementary simulations using frameworks predict that patterned presentation of Jag1 and Dll4 elicits differential sprout morphologies, with Dll4 promoting directed elongation and Jag1 inducing branching, validated against experimental micropatterning assays. Recent extensions include models incorporating heterodimerization, such as JAG1/DLL4 complexes that modulate cis-inhibition and in , as proposed in computational studies. These models integrate Notch with hemodynamic and cues to forecast tissue-scale vascular architecture. Machine learning integration has advanced the quantitative measurement and analysis of Notch signaling. For example, as of 2024, approaches focusing on RBPJ binding sites and genomic features identify robust Notch-responsive enhancers, reducing time for . In 2025 studies, predicted regulators of resistance to Notch signaling blockade in neural stem cells using data. These tools facilitate data-driven refinement of network models by inferring parameter distributions from empirical signaling maps. Systems biology-informed neural networks have also characterized Notch dynamics in development as of 2024. In disease contexts, employs network perturbations to predict oncogenic outcomes from Notch dysregulation in cancer. Boolean dynamic models of signaling networks simulate mutations or overexpression, revealing how hyperactive Notch shifts equilibrium states toward proliferation in or colon tumors. A middle-out extension of colon cancer logical models incorporates Notch perturbations alongside Wnt and MAPK pathways, predicting synergistic responses where gamma-secretase inhibitors restore wild-type dynamics in epithelial cell lines. Similarly, perturbation analyses in multi-scale networks forecast tumor heterogeneity, identifying Notch as a context-dependent hub whose blockade sensitizes resistant subpopulations to . These predictions guide precision by prioritizing interventions that target network vulnerabilities.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.